337 related articles for article (PubMed ID: 23617883)
1. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
[TBL] [Abstract][Full Text] [Related]
2. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.
Bonavia R; Inda MM; Vandenberg S; Cheng SY; Nagane M; Hadwiger P; Tan P; Sah DW; Cavenee WK; Furnari FB
Oncogene; 2012 Sep; 31(36):4054-66. PubMed ID: 22139077
[TBL] [Abstract][Full Text] [Related]
3. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
5. ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Tsai YT; Wu AC; Yang WB; Kao TJ; Chuang JY; Chang WC; Hsu TI
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717924
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
7. C/EBPβ promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma.
Liu X; Liu K; Qin J; Hao L; Li X; Liu Y; Zhang X; Liu X; Li P; Han S; Mao Z; Shen L
Int J Cancer; 2015 Jun; 136(11):2524-34. PubMed ID: 25382637
[TBL] [Abstract][Full Text] [Related]
8. PSMB8 inhibition decreases tumor angiogenesis in glioblastoma through vascular endothelial growth factor A reduction.
Chang HH; Cheng YC; Tsai WC; Chen Y
Cancer Sci; 2020 Nov; 111(11):4142-4153. PubMed ID: 32816328
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
Zhang X; Niu W; Mu M; Hu S; Niu C
J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
11. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
12. EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas.
Zhao K; Wang Q; Wang Y; Huang K; Yang C; Li Y; Yi K; Kang C
Cancer Lett; 2017 Oct; 406():12-21. PubMed ID: 28778566
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
15. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
16. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
17. Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.
Ding C; Luo J; Fan X; Li L; Li S; Wen K; Feng J; Wu G
J Exp Clin Cancer Res; 2017 Apr; 36(1):56. PubMed ID: 28420432
[TBL] [Abstract][Full Text] [Related]
18. The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells.
Tallen G; Farhangi S; Tamannai M; Holtkamp N; Mangoldt D; Shah S; Suzuki K; Truss M; Henze G; Riabowol K; von Deimling A
Oncol Res; 2009; 18(2-3):95-105. PubMed ID: 20066899
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling.
Day EK; Sosale NG; Xiao A; Zhong Q; Purow B; Lazzara MJ
Cell Rep; 2020 Mar; 30(10):3383-3396.e7. PubMed ID: 32160544
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
